What is it about?

Our study demonstrates that beta2 adrenoceptor (AR) agonists, e.g. terbutaline, can specifically induce vasorelaxation of pulmonary but not systemic arteries of mouse. This effect was independent from beta ARs and the endothelium but was mediated by alpha1-adrenolytic activity of the compound. The response was physiologically relevant because it was also found in small intrapulmonary resistance arteries under normoxia and hypoxia. Also when applied as an aerosol in mouse in vivo, a selective decrease of pulmonary arterial pressure was found and no systemic cardiovascular side effects could be detected. Because beta2 AR agonists are standard drugs clinically used for obstructive lung disease, our study establishes a potential dual role of beta2 AR agonists for bronchorelaxation and pulmonary vasorelaxation, which could lead to novel therapeutic options for pulmonary hypertension.

Featured Image

Read the Original

This page is a summary of: The β 2 agonist terbutaline specifically decreases pulmonary arterial pressure under normoxia and hypoxia via a adrenoceptor antagonism, The FASEB Journal, January 2018, Wiley,
DOI: 10.1096/fj.201700684rr.
You can read the full text:

Read

Contributors

The following have contributed to this page